Invitation to Year End 2010 and Q4 Results Conference Call of MorphoSys AG on February 24, 2011

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - February 17, 2011) - MorphoSys AG /

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2010 on February 24, 2011 at 7:00 a.m. CET.

The Management team of MorphoSys AG will host a conference call and audio webcast to present MorphoSys’s Annual Financial Results 2010 and provide an outlook for 2011.

DATE: Thursday, 24th February 2011 TIME: 14:00 p.m. CET (13:00 GMT, 08:00 EST) DIAL IN No: +49 (0) 89 2444 329 75 UK RESIDENTS: +44 (0) 20 3003 2666 US RESIDENTS: +1 212 999 6659 Participants of the call are: Dr. Simon Moroney, Chief Executive Officer Dave Lemus, Chief Financial Officer Dr. Marlies Sproll, Chief Scientific Officer Dr. Arndt Schottelius, Chief Development Officer 

We request that you call the number above up to 10 minutes early to ensure a prompt start and a secure line.

MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at www.morphosys.com

The presentation slides will be available on the Company’s website.

A slide-synchronized audio replay of the conference will be available following the live event on www.morphosys.com

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health- care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit http://www.morphosys.com/

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.

--- End of Message ---

MorphoSys AG Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;

Conference Call Alert YE 2010: http://hugin.info/130295/R/1490179/425794.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1490179]